Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06871774 · ClinicalTrials.gov registry record · NA
Comparison of Single vs. Dual Perclose Devices for Large-Bore Access Closure in TAVR
A NA study of Transcatheter Aortic Valve Replacement, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT06871774 is a NA study of Transcatheter Aortic Valve Replacement that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 300 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06871774, a NA study of Transcatheter Aortic Valve Replacement, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the use of one Perclose device to the usual approach of two devices for pre-closure during Transcatheter Aortic Valve Replacement (TAVR). The study will compare the time it takes for bleeding to stop using the different closure approaches. The study will also compare complications when using one Perclose device versus two.
Conditions Studied
Interventions
- DEVICE Single Perclose Pro vascular closure device
- DEVICE Dual Perclose vascular closure device
Study Locations (1)
Wisconsin
- Aurora St. Luke's Medical Center - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2026-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06871774
The ClinicalTrials.gov registry entry for NCT06871774 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transcatheter Aortic Valve Replacement appearing as the primary indexed condition, and to 2 interventions - of which Single Perclose Pro vascular closure device is the first listed.
NCT06871774 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06871774 about?
NCT06871774 is a clinical study titled "Comparison of Single vs. Dual Perclose Devices for Large-Bore Access Closure in TAVR". This study will compare the use of one Perclose device to the usual approach of two devices for pre-closure during Transcatheter Aortic Valve Replacement (TAVR). The study will compare the time it takes for bleeding to stop using the different closure approaches. The study will also compare complica...
What is the current status of trial NCT06871774?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2025-06-16. Estimated completion is 2026-07.
What conditions does trial NCT06871774 study?
This clinical trial studies the following conditions: Transcatheter Aortic Valve Replacement.
What interventions are being tested in trial NCT06871774?
The interventions under investigation include: Single Perclose Pro vascular closure device (DEVICE), Dual Perclose vascular closure device (DEVICE).
Who is sponsoring clinical trial NCT06871774?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06871774 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transcatheter Aortic Valve Replacement
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.